Status:
COMPLETED
Effects of Transdermal Nicotine on Smoking, Craving and Withdrawal in People With Schizophrenia
Lead Sponsor:
National Institute on Drug Abuse (NIDA)
Conditions:
Schizophrenia and Disorders With Psychotic Features
Tobacco Use Disorder
Eligibility:
All Genders
18-80 years
Phase:
PHASE2
Brief Summary
Individuals with schizophrenia are three times as likely to smoke cigarettes as individuals without schizophrenia. While a great deal of research has been focused on smoking cessation programs for hea...
Detailed Description
Nicotine is the most commonly abused drug among individuals with schizophrenia; at least 60 percent of schizophrenics smoke cigarettes. Nicotine withdrawal may cause a temporary worsening of schizophr...
Eligibility Criteria
Inclusion
- Smokes between 20 and 50 cigarettes per day
- Diagnosis of schizophrenia or schizoaffective disorder
Exclusion
- If enrolled in the control group, must not be diagnosed with a psychiatric disorder
- Currently dependent on alcohol or any drug (other than nicotine)
- Currently trying to quit smoking
- Currently taking bupropion, desipramine, clonidine, buspirone, or doxepin
- History of liver disease
- History of heart attacks or chest pain
- Allergic to adhesives
- Pregnant or breastfeeding
Key Trial Info
Start Date :
June 1 2002
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2005
Estimated Enrollment :
48 Patients enrolled
Trial Details
Trial ID
NCT00218218
Start Date
June 1 2002
End Date
February 1 2005
Last Update
January 12 2017
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Providence VA Medical Center
Providence, Rhode Island, United States, 02908
2
Brown University
Providence, Rhode Island, United States, 02912